A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...
ctDNA offers a minimally invasive alternative for detecting PIK3CA, AKT1, and PTEN alterations in hormone receptor-positive breast cancer when tissue is unavailable. The CAPItello-291 trial showed ...